Today’s Stock On Watch: Will Aduro BioTech Inc Short Squeeze Soon?

Today's Stock On Watch: Will Aduro BioTech Inc Short Squeeze Soon?

The stock of Aduro BioTech Inc (NASDAQ:ADRO) is a huge mover today! The stock decreased 5.96% or $0.9 during the last trading session, hitting $14.2. About 516,225 shares traded hands or 20.46% up from the average. Aduro BioTech Inc (NASDAQ:ADRO) has risen 13.53% since April 13, 2016 and is uptrending. It has outperformed by 9.61% the S&P500.
The move comes after 9 months negative chart setup for the $944.60 million company. It was reported on Nov, 15 by We have $13.06 PT which if reached, will make NASDAQ:ADRO worth $75.57 million less.

Analysts await Aduro BioTech Inc (NASDAQ:ADRO) to report earnings on November, 28. They expect $-0.49 earnings per share, down 5,000.00% or $0.50 from last year’s $0.01 per share. After $0.03 actual earnings per share reported by Aduro BioTech Inc for the previous quarter, Wall Street now forecasts -1,733.33% negative EPS growth.

Aduro BioTech Inc (NASDAQ:ADRO) Ratings Coverage

Out of 6 analysts covering Aduro Biotech (NASDAQ:ADRO), 3 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 50% are positive. Aduro Biotech has been the topic of 9 analyst reports since August 19, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating given on Thursday, September 3 by Zacks. The firm has “” rating given on Wednesday, August 19 by Leerink Swann. The stock of Aduro BioTech Inc (NASDAQ:ADRO) earned “Buy” rating by TH Capital on Tuesday, November 24. The firm earned “Outperform” rating on Tuesday, October 20 by Oppenheimer. FBR Capital maintained the shares of ADRO in a report on Tuesday, May 17 with “Outperform” rating. Oppenheimer downgraded the stock to “Perform” rating in Tuesday, December 1 report. As per Tuesday, November 24, the company rating was maintained by Roth Capital. The firm has “Buy” rating given on Thursday, August 27 by Roth Capital. The firm has “Underperform” rating by Bank of America given on Tuesday, March 15.

According to Zacks Investment Research, “Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is based in BERKELEY, United States.”

More recent Aduro BioTech Inc (NASDAQ:ADRO) news were published by: which released: “Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase …” on November 12, 2016. Also published the news titled: “Form 4 ADURO BIOTECH, INC. For: Nov 10 Filed by: Lew Jennifer” on November 15, 2016.‘s news article titled: “Why Aduro Biotech Is Crashing Today” with publication date: November 24, 2015 was also an interesting one.

ADRO Company Profile

Aduro Biotech, Inc., incorporated on May 5, 2011, is a clinical-stage immunotherapy company. The Firm is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Firm has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. The Company’s LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, LADD technology platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. The Company’s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. The Company’s B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment